Allogene Therapeutics, Inc. (ALLO)
$
2.21
-0.23 (-10.41%)
Key metrics
Financial statements
Free cash flow per share
-0.6782
Market cap
538.7 Million
Price to sales ratio
0
Debt to equity
0.2846
Current ratio
7.9273
Income quality
0.7819
Average inventory
0
ROE
-0.5707
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company that focuses on the development and commercialization of genetically engineered allogeneic T cell therapies to combat cancer. The company reported depreciation and amortization expenses of $12,359,000.00 reflecting the wear and tear of its assets, which is a vital element in assessing its financial health. The weighted average number of shares outstanding is 220,622,669.00 highlighting the company's shareholder base and its appeal to investors. Allogene’s operating expenses amount to $194,574,000.00 encompassing various operational costs incurred during its innovative development processes. The cost of revenue for the company is $12,359,000.00 showcasing its production and operational expenses, which are crucial to its overall profitability. Consequently, the gross profit stands at -$12,359,000.00 highlighting the company's financial performance from core operations as it champions the fight against cancer. The company develops, manufactures, and commercializes products like UCART19 for R/R CD19 positive B-cell ALL, and several other promising candidates for various cancers, thus forming a diverse product portfolio that underscores its dedication to improving patient outcomes. The stock is affordable at $1.16 suitable for budget-conscious investors, making it accessible to a wider range of potential shareholders. Additionally, the stock has a high average trading volume of 5,621,983.00 indicating strong liquidity, which is often a desirable trait for active traders. With a market capitalization of $538,749,183.00 the company is classified as a small-cap player, positioning it uniquely within the market. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, driving innovation and growth, which enhances its reputation and attractiveness as an investment option. Through strategic collaborations and groundbreaking research, Allogene Therapeutics, Inc. continues to be a forward-thinking entity in the competitive field of immuno-oncology.
Is Allogene Therapeutics, Inc. (ALLO) a good investment?
Investing in Allogene Therapeutics, Inc. (ALLO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Allogene Therapeutics, Inc. (ALLO)'s stock forecast?
Analysts predict Allogene Therapeutics, Inc. stock to fluctuate between $0.86 (low) and $2.80 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Allogene Therapeutics, Inc.'s market capitalization?
As of 2026-03-25, Allogene Therapeutics, Inc.'s market cap is $538,749,183, based on 243,777,911 outstanding shares.
How does Allogene Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Allogene Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Allogene Therapeutics, Inc. (ALLO) stock?
To buy Allogene Therapeutics, Inc. (ALLO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALLO. Place an order (Market, Limit, etc.).
What is the best time to invest in Allogene Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Allogene Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.87 | Growth: -34.09%.
Where can I find Allogene Therapeutics, Inc.'s investor relations reports?
Visit https://www.allogene.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Allogene Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Allogene Therapeutics, Inc. stock?
All-time high: $27.86 (2021-09-23) | All-time low: $0.86 (2025-05-14).
What are the key trends affecting Allogene Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
globenewswire.com
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
zacks.com
Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.
zacks.com
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
zacks.com
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December.
seekingalpha.com
Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility analysis in H1 2026, but must proceed without ALLO-647. ALLO-316 showed a 31% response rate in advanced RCC patients with CD70+ TPS ≥50%, but future studies will require this narrow focus.
zacks.com
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
seekingalpha.com
Allogene Therapeutics, Inc. ( ALLO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Geoffrey Parker - Executive VP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Tyler Van Buren - TD Cowen, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Samantha Corwin - William Blair & Company L.L.C.
See all news
